BioVie Inc. (NASDAQ: BIVI)
BIVI · Nasdaq · United States
Share price · BIVI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BIVI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-22.5%
- 3 Nov 2026+26.3%
- 20 Aug 2026+38.8%
Nothing announced by BIVI that day or the session before.
- 19 Aug 2026+38.9%
Nothing announced by BIVI that day or the session before.
- 12 Aug 2026+22.8%
Nothing announced by BIVI that day or the session before.
- 7 Aug 2026-26.0%
- 6 Aug 2026-33.8%
- 20 Jul 2026-20.8%
Nothing announced by BIVI that day or the session before.
- 13 Jul 2026-27.8%
Nothing announced by BIVI that day or the session before.
- 2 Jul 2026-10.6%
Nothing announced by BIVI that day or the session before.
Share of unusual movement by asset
For each asset, the share of BIVI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | ERK/NF-kB inflammatorySmall molecule | Alzheimer's DiseaseParkinson's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $3.3M | $7.7M | $5.6M-$2.9M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $3.2M | $13M | $5.3M-$7.4M operating cash flow | report ↗ |
| 2025-Q4 | — | $4.3M | $21M | $6.1M-$4.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.9M | $25M | $5.1M-$3.0M operating cash flow | report ↗ |
| 2025-Q1 | — | $1.3M | $23M | $2.8M-$1.3M operating cash flow | report ↗ |
| 2024-Q4 | — | $4.7M | $24M | $7.1M-$8.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.0M | $20M | $4.2M-$3.6M operating cash flow | report ↗ |
| 2024-Q1 | — | $5.7M | $30M | $8.1M-$5.8M operating cash flow | report ↗ |
| 2023-Q4 | — | $6.5M | $20M | $8.4M-$5.9M operating cash flow | report ↗ |
| 2023-Q3 | — | $8.9M | $21M | $11M-$12M operating cash flow | report ↗ |
| 2023-Q1 | — | $11M | $31M | $15M-$12M operating cash flow | report ↗ |
| 2022-Q4 | — | $7.0M | $46M | $16M-$8.0M operating cash flow | report ↗ |
| 2022-Q3 | — | $6.8M | $21M | $10M-$9.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $3.6M | $25M | $7.0M-$5.9M operating cash flow | report ↗ |
| 2021-Q4 | — | $4.6M | $30M | $5.4M-$4.7M operating cash flow | report ↗ |
| 2021-Q3 | — | $2.9M | $20M | $5.5M-$2.5M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | — | $14M | $9.0M | $5.5M-$19M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $9.3M | $18M | $4.4M-$19M operating cash flow | report ↗ |
| 2024-FY | — | $23M | $24M | $8.0M-$28M operating cash flow | report ↗ |
| 2023-FY | — | $33M | $19M | $13M-$40M operating cash flow | report ↗ |
| 2022-FY | — | $17M | $19M | $6.5M-$19M operating cash flow | report ↗ |
| 2021-FY | — | $133M | $4.5M | $33M-$10M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($55K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | DO CUONG V · director, President & CEO | Open-market purchase | 2,500 | $1.00 | $2K | Form 4 |
| 2026-11-13 | DO CUONG V · director, President & CEO | Open-market purchase | 2,500 | $1.16 | $3K | Form 4 |
| 2026-08-28 | KIM JOANNE WENDY · Chief Financial Officer | Open-market purchase | 2,500 | $2.18 | $5K | Form 4 |
| 2026-08-28 | Chappell Amy Suzon · director | Open-market purchase | 727 | $2.16 | $2K | Form 4 |
| 2026-08-28 | Palumbo Joseph M · Chief Medical Officer | Open-market purchase | 4,843 | $2.16 | $10K | Form 4 |
| 2026-08-27 | DO CUONG V · director, President & CEO | Open-market purchase | 15,210 | $2.08 | $32K | Form 4 |
| 2026-01-05 | Lang James Paul · director | Award / grant (derivative) | 90,000 | — | — | Form 4 |
| 2026-01-05 | Chappell Amy Suzon · director | Award / grant (derivative) | 57,500 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 1.0M shares ($1.3M, 13.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Diametric Capital, LP | 370,000 | $518K |
| 2 | PRELUDE CAPITAL MANAGEMENT, LLC | 92,063 | $129K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 84,203 | $118K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 84,067 | $118K |
| 5 | MORGAN STANLEY | 75,221 | $105K |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 67,918 | $95K |
| 7 | CITADEL ADVISORS LLC | 45,292 | $63K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 37,557 | $53K |
| 9 | JANE STREET GROUP, LLC | 22,791 | $32K |
| 10 | XTX Topco Ltd | 21,226 | $30K |
| 11 | NORTHERN TRUST CORP | 14,189 | $20K |
| 12 | Tower Research Capital LLC (TRC) | 7,540 | $11K |
| 13 | Allworth Financial LP | 5,600 | $8K |
| 14 | CITIGROUP INC | 3,164 | $4K |
| 15 | PNC FINANCIAL SERVICES GROUP, INC. | 1,000 | $1K |